We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Read MoreHide Full Article
ARIAD Pharmaceuticals, Inc. presented updated data from a pivotal phase II study (ALTA) on its most advanced pipeline candidate brigatinib, in patients with ALK+ non-small cell lung cancer (NSCLC) who had experienced disease progression on Pfizer Inc.’s (PFE - Free Report) Xalkori therapy. Data were presented at the annual meeting of the American Society of Clinical Oncology.
Results from the study showed that among the patients with a median follow-up of 8.3 months, when treated with brigatinib (180 mg), a confirmed objective response (primary endpoint) of 54% was observed. Moreover, the median progression free survival was found to be greater than one year (12.9 months) in the post-Xalkori setting. In addition, patients with measurable brain metastases demonstrated a 67% confirmed intracranial objective response rate.
ARIAD is on track to file a new drug application for brigatinib in the third quarter of 2016. We note that brigatinib has Orphan Drug status in the U.S. for the treatment of ALK+NSCLC. It also enjoys Breakthrough Therapy status in the U.S. for the treatment of patients with ALK+NSCLC that is resistant to Xalkori.
Meanwhile, ARIAD has also initiated the phase III ALTA first-line study comparing the efficacy of brigatinib to Xalkori.
Apart from brigatinib, the only other candidate in the company’s pipeline is AP32788, which is in a phase I/II study for the treatment of patients with NSCLC with specific mutations in EGFR or HER2.
Currently, the only marketed product in ARIAD’s portfolio is Iclusig, which is a leukemia drug.
ARIAD is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are Juniper Pharmaceuticals, Inc. , sporting a Zacks Rank #1 (Strong Buy) and Actinium Pharmaceuticals, Inc. (ATNM - Free Report) carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
ARIAD Pharmaceuticals, Inc. presented updated data from a pivotal phase II study (ALTA) on its most advanced pipeline candidate brigatinib, in patients with ALK+ non-small cell lung cancer (NSCLC) who had experienced disease progression on Pfizer Inc.’s (PFE - Free Report) Xalkori therapy. Data were presented at the annual meeting of the American Society of Clinical Oncology.
Results from the study showed that among the patients with a median follow-up of 8.3 months, when treated with brigatinib (180 mg), a confirmed objective response (primary endpoint) of 54% was observed. Moreover, the median progression free survival was found to be greater than one year (12.9 months) in the post-Xalkori setting. In addition, patients with measurable brain metastases demonstrated a 67% confirmed intracranial objective response rate.
ARIAD is on track to file a new drug application for brigatinib in the third quarter of 2016. We note that brigatinib has Orphan Drug status in the U.S. for the treatment of ALK+NSCLC. It also enjoys Breakthrough Therapy status in the U.S. for the treatment of patients with ALK+NSCLC that is resistant to Xalkori.
Meanwhile, ARIAD has also initiated the phase III ALTA first-line study comparing the efficacy of brigatinib to Xalkori.
Apart from brigatinib, the only other candidate in the company’s pipeline is AP32788, which is in a phase I/II study for the treatment of patients with NSCLC with specific mutations in EGFR or HER2.
Currently, the only marketed product in ARIAD’s portfolio is Iclusig, which is a leukemia drug.
ARIAD is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are Juniper Pharmaceuticals, Inc. , sporting a Zacks Rank #1 (Strong Buy) and Actinium Pharmaceuticals, Inc. (ATNM - Free Report) carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>